Your browser doesn't support javascript.
loading
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy.
De Giglio, Andrea; Di Federico, Alessandro; Gariazzo, Eleonora; Metro, Giulio.
Affiliation
  • De Giglio A; Department of Medical and Surgical Sciences, University of Bologna, Via Albertoni 15, 40138 Bologna, Italy. Electronic address: andrea.degiglio2@unibo.it.
  • Di Federico A; Department of Medical and Surgical Sciences, University of Bologna, Via Albertoni 15, 40138 Bologna, Italy.
  • Gariazzo E; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, via Dottori, 1, 06156 Perugia, Italy.
  • Metro G; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, via Dottori, 1, 06156 Perugia, Italy.
Med ; 5(1): 1-3, 2024 Jan 12.
Article in En | MEDLINE | ID: mdl-38218173
ABSTRACT
The PAPILLON trial showed that adding amivantamab to carboplatin-pemetrexed for advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations is more effective than chemotherapy. Although safety concerns may arise, this study highlights the need for alternative therapeutic strategies beyond chemotherapy for this subtype of NSCLC.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Bispecific / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: En Journal: Med Year: 2024 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Bispecific / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: En Journal: Med Year: 2024 Type: Article